Figure 3From: Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibeChanges in inflammatory markers and MDA-LDL levels between baseline and 12 weeks after randomization. hs-CRP, high sensitivity-C-reactive protein; IL-6, interleukin-6; MDA-LDL, malondialdehyde-modified-low-density lipoprotein; PTX3, pentraxin 3; TNF-α, tumour necrosis factor-α.Back to article page